Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 19/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 17/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12257260 | 0.90 | SLC5A2 (0.83) | SLC5A2SLC5A1 | |
| SCHEMBL12257545 | 0.89 | SLC5A2 (0.81) | SLC5A2SLC5A1 | |
| SCHEMBL10084156 | 0.88 | SLC5A2 (1.00) | SLC5A2SLC5A1CYP3A4 | |
| SCHEMBL13425482 | 0.85 | SLC5A2 (0.77) | SLC5A2SLC5A1 | |
| SCHEMBL10076559 | 0.85 | SLC5A2 (0.74) | SLC5A2SLC5A1 | |
| SCHEMBL12336535 | 0.85 | SLC5A2 (0.73) | SLC5A2SLC5A1CYP3A4 | |
| SCHEMBL14128497 | 0.83 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL15014653 | 0.81 | SLC5A2 (0.68) | SLC5A2SLC5A1CYP3A4 | |
| SCHEMBL13425485 | 0.80 | SLC5A1 (0.78) | SLC5A2SLC5A1 | |
| SCHEMBL12257547 | 0.80 | SLC5A2 (0.85) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2829271-A2 | Pharmaceutical compositions with (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol and a further antidiabetic agent | Taisho Pharmaceutical Co., Ltd. (JP) | 2015-01-28 | — | — | EP | disclosed |
| US-20120040898-A1 | PHARMACEUTICAL COMPOSITIONS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2012-02-16 | — | — | US | disclosed |
| US-8017792-B2 | 1-thio-D-glucitol derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-8017792-B2 | 1-thio-D-glucitol derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20110098469-A1 | 1-THIO-D-GLUCITOL DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20110098469-A1 | 1-THIO-D-GLUCITOL DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| US-7910619-B2 | e.g. 2,3,4,6-tetra-O-benzyl-5-thio-D-glucono-1,5-lactone3,4-Dihydro-2H-pyran; inhibit the activity of sodium-dependent glucose cotransporter 2 (SGLT2) concerned with glucose reabsorption in the kidney; antidiabetic agent; diabetes-related disease, or diabetic complication | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| US-7910619-B2 | e.g. 2,3,4,6-tetra-O-benzyl-5-thio-D-glucono-1,5-lactone3,4-Dihydro-2H-pyran; inhibit the activity of sodium-dependent glucose cotransporter 2 (SGLT2) concerned with glucose reabsorption in the kidney; antidiabetic agent; diabetes-related disease, or diabetic complication | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| WO-2010119990-A1 | PHARMACEUTICAL COMPOSITIONS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-21 | — | — | WO | disclosed |
| US-20080132563-A1 | 1-Thio-D-Glucitol Derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| US-20080132563-A1 | 1-Thio-D-Glucitol Derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1845095-A1 | 1-THIO-D-GLUCITOL DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098469-A1 | 1-THIO-D-GLUCITOL DERIVATIVES | SLC5A1, SLC5A2, SLC5A11 | SLC5A2 2/4885SLC5A1 1/4885CYP3A4 1226/4885 |
| US-20120040898-A1 | PHARMACEUTICAL COMPOSITIONS | DPP4, GLP1R, SLC5A1 | SLC5A2 11/4885SLC5A1 3/4885CYP3A4 538/4885 |
| US-20080132563-A1 | 1-Thio-D-Glucitol Derivatives | SLC5A1, SLC5A2, SLC5A11 | SLC5A2 2/4885SLC5A1 1/4885CYP3A4 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.